Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Fakharian
 
IRCT20151227025726N2
RCTadalimumabCOVID-19 severe or criticallysome concern
34/34 ongoing
    CAN-COVID
     
    NCT04362813
    RCTcanakinumabplaceboCOVID-19 severe or criticallysome concern
    227/227 inconclusive
    • inconclusive 39 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
    2 studies excluded by filtering options (2 RCT / 0 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).